Abstract
The use of intravitreal anti vascular endothelial growth factor (anti-VEGF) drugs such as pegaptanib, ranibizumab and bevacizumab has been widely reported to treat complications such as macular edema and rubeosis. During the past few years they have also been used as an adjuvant therapy to reduce intraocular bleeding during vitrectomy in eyes with proliferative diabetic retinopathy as well as to reduce the occurrence of vitreous haemorrhages in vitrectomized eyes and facilitate glaucoma surgery.
In this paper we review the use of anti VEGF drugs in the surgical management of diabetic retinopathy related complications.
Keywords: Diabetic retinopathy, Proliferative diabetic retinopathy, Diabetic macular edema, VEGF, Bevacizumab, Ranibizumab, Pegaptanib, Bevasiranib, VEGF trap, Vitrectomy, Laser photocoagulation, Phacoemulsification, Glaucoma surgery
Current Diabetes Reviews
Title: Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Volume: 7 Issue: 3
Author(s): Javier A. Montero, Jose M Ruiz-Moreno and Maria E. Correa
Affiliation:
Keywords: Diabetic retinopathy, Proliferative diabetic retinopathy, Diabetic macular edema, VEGF, Bevacizumab, Ranibizumab, Pegaptanib, Bevasiranib, VEGF trap, Vitrectomy, Laser photocoagulation, Phacoemulsification, Glaucoma surgery
Abstract: The use of intravitreal anti vascular endothelial growth factor (anti-VEGF) drugs such as pegaptanib, ranibizumab and bevacizumab has been widely reported to treat complications such as macular edema and rubeosis. During the past few years they have also been used as an adjuvant therapy to reduce intraocular bleeding during vitrectomy in eyes with proliferative diabetic retinopathy as well as to reduce the occurrence of vitreous haemorrhages in vitrectomized eyes and facilitate glaucoma surgery.
In this paper we review the use of anti VEGF drugs in the surgical management of diabetic retinopathy related complications.
Export Options
About this article
Cite this article as:
A. Montero Javier, M Ruiz-Moreno Jose and E. Correa Maria, Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery, Current Diabetes Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339911795843104
DOI https://dx.doi.org/10.2174/157339911795843104 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Syndrome of Supine Hypertension with Orthostatic Hypotension: Pathophysiology and Clinical Approach
Current Cardiology Reviews Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease
Current Clinical Pharmacology Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Heart Failure in South America
Current Cardiology Reviews Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Genetic Diversity Among Saudi Peganum harmala and Rhazya stricta Populations Using Chemical and ISSR Markers
Current Pharmaceutical Biotechnology Recent Achievements on Siderophore Production and Application
Recent Patents on Biotechnology Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism Improved Sensory Blockade by Clonidine Added to Axillary Block Solution. Resulting Plasma Clonidine Concentration
Letters in Drug Design & Discovery Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Strategies to Reduce Oxidative Stress in Glaucoma Patients
Current Neuropharmacology Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology